Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Acq. announced
Appointed director
Ocuphire Pharma, Inc. (OCUP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Quarterly results
05/15/2023 8-K Investor presentation, Quarterly results
Docs: "End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced Mydriasis Set for September 28, 2023; Nyxol Development and Commercialization Funded by Viatris",
"Corporate Presentation"
08/12/2022 8-K Investor presentation, Quarterly results
Docs: "Positive Results from Phase 3 LYNX-1 Trial of Nyxol in Night Vision Disturbances Mark Sixth Positive Nyxol Clinical Data Readout Across Multiple Indications Data Expected in 2H 2022 from Phase 2b Trial of APX3330, a Potential First-in-Class Oral Treatment for Diabetic Retinopathy",
"Corporate Presentation"
05/13/2022 8-K Quarterly results
03/24/2022 8-K Quarterly results
Docs: "Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials"
08/12/2021 8-K Investor presentation, Quarterly results
Docs: "Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update",
"Corporate Presentation"
05/07/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
08/07/2019 8-K Quarterly results
Docs: "ROCKVILLE, MD – August 7, 2019"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy